Review the ECLIPSE study published in New England Journal of Medicine.  See the data

Blood-based CRC screening fits right in.
Simply done.

Rack of test tubes with blood.

ShieldTM is a blood test that can be completed at any patient visit1

A blood-based approach is the patient-preferred screening option for CRC2*

Patients icon.

This option fits into patients’ schedules and breaks through screening
barriers since it requires3

No special preparation
No dietary changesNo sedation
No sedationNo dietary changes
No extra time away
from family or work
Doctor icon.

It also fits right into a provider’s practice

If providers can order a complete blood count for their patients, they’re equipped to order
a blood-based CRC screening test.2

Shield demonstrated 90% compliance in real-world clinical settings.4†

The ECLIPSE study, published in New England Journal of Medicine, validated Shield as a high-sensitivity blood test for CRC screening that is easy to complete1‡§

CRC Overall


Negative predictive value

ECLIPSE was one of the largest studies and the first of its kind
to validate a blood test that detects CRC with high sensitivity1,5

  • Validated Shield in over 10,000 patients
  • Included a diverse population representative of US demographics with broad ethnic and socioeconomic backgrounds1,5||
  • Patients aged 45 to 84 at average risk for CRC

Results were consistent with a growing body of evidence that demonstrates the high sensitivity of our blood-based technology.6

How Guardant Health’s blood-based approach identifies CRC

Our technology achieves high sensitivity by applying a multimodal approach to detect CRC signals in the bloodstream, including DNA that is shed by tumors.1

Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.

*In a study, patients who initially refused colonoscopy preferred screening with a blood-based test over a stool-based test 83% vs 15%, respectively.2

Compliance rate for the first 20,000 patients who were prescribed Shield.4

The ECLIPSE study (NCT04136002) is comparing the sensitivity and specificity of cell-free DNA (cfDNA)-only Shield with findings from subsequent colonoscopy in over 10,000 average-risk patients.1

§Patients had no prior diagnosis of CRC, inflammatory bowel disease, or family history of genetic risk for CRC (eg, Lynch syndrome).7 Specificity detected for advanced neoplasia in ECLIPSE includes CRC and advanced adenomas; overall sensitivity shown is for CRC.1

||With more than 200 clinical trial sites in rural and urban communities across 34 states, study participant demographics included 12% Black, 13% Hispanic, and 7% Asian American populations. The study achieved above-average enrollment among Black Americans for a clinical trial.1,5

Shield™ is a qualitative laboratory developed test intended to detect colorectal cancer by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
  • The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
  • Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
  • A "normal signal detected" Shield test result does not preclude the presence of colorectal cancer, and patients should continue participating in guideline-recommended screening programs
  • Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
References 1. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973-983. doi:10.1056/NEJMoa2304714 2. Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:183. doi:10.1186/1471-230X-14-183 3. Rich T, Raymond V, Lang K. Where are we today? Efforts to understand strategies and barriers to physician issuance of a recommendation for colorectal cancer screening: a systematic review. Gastroenterology. 2020;158(6 suppl 1):S-918. doi:10.1016/S0016-5085(20)32981-4 4. Data on file. Guardant Health, Inc. 5. Guardant Health ECLIPSE Study data demonstrating efficacy of Shield blood-based test for colorectal cancer screening to be published in the New England Journal of Medicine. March 13, 2024. Accessed March 15, 2024. 6. D’Auria K, Chang Y, Multhaup M, et al. Validation of a multi-modal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Chicago, IL. 7. Evaluation of the ctDNA LUNAR test in an average patient screening episode (ECLIPSE). identifier: NCT04136002. Updated September 22, 2021. Accessed November 24, 2021.